LTRN Lantern Pharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LTRN

Price (delayed)

$5.34

Market cap

$57.36M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.47

Enterprise value

$35.66M

Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical company innovating the repurposing, revitalization and development of precision therapeutics in oncology. It leverages advances in machine learning, genomics, and artificial intelligence by ...

Highlights
The company's debt fell by 15% QoQ
The equity has contracted by 27% YoY and by 10% from the previous quarter
The quick ratio has contracted by 23% from the previous quarter and by 23% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.lanternpharma.com
Peers: OMER OMGA

Key stats

What are the main financial stats of LTRN
Market
Shares outstanding
10.74M
Market cap
$57.36M
Enterprise value
$35.66M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.42
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$15.96M
EBITDA
-$15.79M
Free cash flow
-$14.37M
Per share
EPS
-$1.47
Free cash flow per share
-$1.32
Book value per share
$3.76
Revenue per share
$0
TBVPS
$4.03
Balance sheet
Total assets
$43.65M
Total liabilities
$2.74M
Debt
$234,471
Equity
$40.91M
Working capital
$40.66M
Liquidity
Debt to equity
0.01
Current ratio
16.18
Quick ratio
15.42
Net debt/EBITDA
1.37
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-32.2%
Return on equity
-34.1%
Return on invested capital
-80.6%
Return on capital employed
-39%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LTRN stock price

How has the Lantern Pharma stock price performed over time
Intraday
-7.45%
1 week
-16.43%
1 month
-28.7%
1 year
6.8%
YTD
24.77%
QTD
-39.32%

Financial performance

How have Lantern Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$17.88M
Net income
-$15.96M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 24% year-on-year and by 6% since the previous quarter
The company's net income fell by 12% YoY and by 5% QoQ

Growth

What is Lantern Pharma's growth rate over time

Valuation

What is Lantern Pharma stock price valuation
P/E
N/A
P/B
1.42
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Lantern Pharma's EPS has decreased by 12% YoY and by 5% from the previous quarter
LTRN's price to book (P/B) is 29% higher than its last 4 quarters average of 1.1
The equity has contracted by 27% YoY and by 10% from the previous quarter

Efficiency

How efficient is Lantern Pharma business performance
The ROE has contracted by 44% YoY and by 14% from the previous quarter
Lantern Pharma's return on assets has decreased by 44% YoY and by 13% QoQ
The return on invested capital has declined by 4.1% since the previous quarter and by 3.6% year-on-year

Dividends

What is LTRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LTRN.

Financial health

How did Lantern Pharma financials performed over time
The total assets is down by 26% year-on-year and by 9% since the previous quarter
The quick ratio has contracted by 23% from the previous quarter and by 23% YoY
The company's debt is 99% lower than its equity
The equity has contracted by 27% YoY and by 10% from the previous quarter
The company's debt fell by 15% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.